PRESS RELEASE

Q4 2023 — Press release

Q4 2023PDF · 14 pages344 KB
News Release
____________________________________________________________________________
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
- 	Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and
Vaccines
- 	Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth
Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the
Impact of Foreign Exchange, Growth Was 13%
- 	Fourth-Quarter GAAP Loss per Share Was $0.48; Non-GAAP EPS Was $0.03; GAAP
Loss per Share and Non-GAAP EPS Include a Charge of $1.69 per Share for a
Collaboration With Daiichi Sankyo
- 	Full-Year Worldwide Sales Were $60.1 Billion, an Increase of 1% From Full-Year 2022;
Excluding LAGEVRIO, Growth Was 9%; Excluding LAGEVRIO and the Impact of
Foreign Exchange, Growth Was 12%
o 	KEYTRUDA Sales Grew 19% to $25.0 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 21%
o 	GARDASIL/GARDASIL 9 Sales Grew 29% to $8.9 Billion; Excluding the Impact
of Foreign Exchange, Sales Grew 33%
o 	LAGEVRIO Sales Declined 75% to $1.4 Billion; Excluding the Impact of Foreign
Exchange, Sales Declined 74%
- 	Full-Year 2023 GAAP EPS Was $0.14; Non-GAAP EPS Was $1.51; GAAP and Non-
GAAP EPS Include Charges of $6.21 per Share for Certain Business Development
Transactions
- 	Obtained FDA Priority Review of Biologics License Applications for V116, an
Investigational Pneumococcal Conjugate Vaccine, as Well as Merck and Daiichi
Sankyo’s Patritumab Deruxtecan, in the Fourth Quarter
- 	Received Multiple FDA Approvals Across Oncology Portfolio in 2023
- 	Initiated More Than 20 Phase 3 Study Starts, Including the Progression of Eight Novel
Assets Into Phase 3 in 2023
- 	Augmented Pipeline Through Acquisitions of Prometheus and Imago, and Collaboration
Agreements With Daiichi Sankyo and Kelun-Biotech in 2023
- 	Full-Year 2024 Financial Outlook
o 	Anticipates Worldwide Sales To Be Between $62.7 Billion and $64.2 Billion
o 	Expects Non-GAAP EPS To Be Between $8.44 and $8.59
RAHWAY, N.J., Feb. 1, 2024 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the fourth quarter and full year of 2023.
“2023 was another very strong year for Merck. I am extremely pleased by the progress
we’ve made to develop and deliver transformative therapies and vaccines that will help save

-- 1 of 14 --

- 2 -
and improve lives around the world. We reached more than 500 million people with our
medicines last year alone, over half of which were donations, including through our program to
treat river blindness,” said Robert M. Davis, chairman and chief executive officer, Merck. “We
also made investments of approximately $30 billion in research and development in our ongoing
effort to discover, develop and collaborate to propel the next generation of impactful
innovations. As we move forward, I’m confident that our strong momentum will continue,
underpinned by the unwavering dedication of our talented global team.”
Financial Summary
$ in millions,
except EPS
amounts
Fourth Quarter 	Year Ended
2023 	2022 	Change
Change Ex-
Exchange
Dec. 31,
2023
Dec. 31,
2022 	Change
Change Ex-
Exchange
Sales 	$14,630 	$13,830 	6% 	7% 	$60,115 	$59,283 	1% 	4%
GAAP net
(loss) income1 	(1,226) 	3,017 	N/M 	N/M 	365 	14,519 	-97% 	-95%
Non-GAAP net
income that
excludes
certain
items 1,2* 	66 	4,129 	-98% 	N/M 	3,837 	19,005 	-80% 	-75%
GAAP EPS 	(0.48) 	1.18 	N/M 	N/M 	0.14 	5.71 	-98% 	-95%
Non-GAAP
EPS that
excludes
certain items 2* 	0.03 	1.62 	-98% 	N/M 	1.51 	7.48 	-80% 	-75%
*Refer to table on page 9.
N/M - Not meaningful
Generally Accepted Accounting Principles (GAAP) loss/earnings per share (EPS)
assuming dilution was a loss per share of $0.48 for the fourth quarter and EPS of $0.14 for the
full year of 2023. Non-GAAP EPS was $0.03 for the fourth quarter and $1.51 for the full year of
2023. GAAP loss per share and non-GAAP EPS in the fourth quarter of 2023 include a charge
of $1.69 per share related to the collaboration with Daiichi Sankyo. GAAP and non-GAAP EPS
for the full years of 2023 and 2022 include charges of $6.21 and $0.22 per share, respectively,
related to certain collaborations, licensing agreements and asset acquisitions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, including pretax
intangible asset impairment research and development (R&D) charges of $779 million in the
fourth quarter and full year of 2023 related to gefapixant, and $780 million and $1.7 billion in the
1 Net (loss) income attributable to Merck & Co., Inc.
2 Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior
to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this
release.

-- 2 of 14 --

- 3 -
fourth quarter and full year of 2022, respectively, primarily related to nemtabrutinib. Non-GAAP
EPS also excludes restructuring costs, including costs for the recently approved 2024
Restructuring Program, as well as income and losses from investments in equity securities.
Fourth-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Fourth Quarter
$ in millions 	2023 	2022 	Change
Change
Ex-
Exchange 	Commentary
Total Sales 	$14,630 	$13,830 	6% 	7%
Pharmaceutical 	13,141 	12,180 	8% 	8%
Increase driven by growth in oncology,
vaccines and hospital acute care, partially
offset by a decline in virology, due to
LAGEVRIO, and diabetes. Excluding
LAGEVRIO and impact of foreign exchange,
growth of 14%.
KEYTRUDA 	6,608 	5,450 	21% 	22%
Growth driven by increased global uptake in
earlier-stage indications, including triple-
negative breast cancer and renal cell
carcinoma (RCC), and continued strong global
demand from metastatic indications.
GARDASIL/
GARDASIL 9 	1,871 	1,470 	27% 	27%
Growth due to strong global demand,
particularly in China, and public-sector buying
patterns in the U.S.
JANUVIA/JANUMET 	787 	913 	-14% 	-13%
Decline primarily due to generic competition in
several international markets, particularly in
Europe, and lower demand in the U.S.
PROQUAD, M-M-R II
and VARIVAX 	545 	526 	4% 	3% 	Growth largely due to higher pricing in the U.S.
BRIDION 	429 	441 	-3% 	-3%
Decline primarily due to generic competition in
certain ex-U.S. markets, particularly in Europe,
partially offset by higher demand in the U.S.
Lynparza* 	315 	292 	8% 	8%
Growth driven primarily by higher pricing in the
U.S.
Lenvima* 	226 	216 	5% 	5%
Growth primarily due to higher demand in the
U.S., partially offset by timing of shipments in
China.
LAGEVRIO 	193 	825 	-77% 	-76%
Decline due to nonrecurrence of sales in the
U.K. and lower demand in Japan and
Australia.
ROTATEQ 	185 	139 	34% 	33%
Growth primarily due to public-sector buying
patterns in the U.S. and timing of shipments in
China.
VAXNEUVANCE 	176 	138 	28% 	26%
Growth largely driven by launches in Europe
and continued uptake for the pediatric
indication in the U.S. Prior-year quarter
benefited from inventory stocking in the U.S. in
preparation for pediatric launch.
Animal Health 	1,278 	1,230 	4% 	4%
Growth primarily driven by higher demand for
Companion Animal products.
Livestock 	808 	814 	-1% 	0%
Decline primarily due to timing of shipments for
ruminant products, largely offset by higher
pricing across the product portfolio and higher
demand for swine products.

-- 3 of 14 --

- 4 -
Fourth Quarter
$ in millions 	2023 	2022 	Change
Change
Ex-
Exchange 	Commentary
Companion Animal 	470 	416 	13% 	12%
Growth primarily due to higher demand and
timing of shipments for BRAVECTO line of
products, as well as higher pricing. Sales of
BRAVECTO were $197 million and $168
million in the current and prior-year quarters,
respectively, which represented growth of
18%, or 19% excluding the impact of foreign
exchange.
Other Revenues** 	211 	420 	-50% 	-1%
Decline primarily due to impact of revenue
hedging activities.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
Full-Year Revenue Performance
The following table reflects sales of the company’s top pharmaceutical products, as well
as sales of Animal Health products.
Year Ended
$ in millions 	Dec. 31, 2023 	Dec. 31, 2022 	Change
Change Ex-
Exchange
Total Sales 	$60,115 	$59,283 	1% 	4%
Pharmaceutical 	53,583 	52,005 	3% 	5%
KEYTRUDA 	25,011 	20,937 	19% 	21%
GARDASIL/GARDASIL 9 	8,886 	6,897 	29% 	33%
JANUVIA/JANUMET 	3,366 	4,513 	-25% 	-23%
PROQUAD, M-M-R II and VARIVAX 	2,368 	2,241 	6% 	6%
BRIDION 	1,842 	1,685 	9% 	11%
LAGEVRIO 	1,428 	5,684 	-75% 	-74%
Lynparza* 	1,199 	1,116 	7% 	9%
Lenvima* 	960 	876 	10% 	11%
ROTATEQ 	769 	783 	-2% 	-1%
VAXNEUVANCE 	665 	170 	N/M 	N/M
Animal Health 	5,625 	5,550 	1% 	3%
Livestock 	3,337 	3,300 	1% 	4%
Companion Animal 	2,288 	2,250 	2% 	3%
Other Revenues** 	907 	1,728 	-48% 	-15%
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
N/M - Not meaningful
Full-year 2023 pharmaceutical sales grew 3% to $53.6 billion. Pharmaceutical sales
growth was primarily driven by higher sales in oncology, particularly KEYTRUDA, higher sales
of vaccines, reflecting strong growth of combined sales of GARDASIL/GARDASIL 9 and
VAXNEUVANCE, as well as growth in hospital acute care products, including PREVYMIS and
BRIDION. Pharmaceutical sales growth in 2023 was partially offset by lower sales of the
COVID-19 medication LAGEVRIO, as well as lower sales of JANUVIA and JANUMET, primarily
reflecting generic competition in many ex-U.S. markets and lower demand in the U.S., and
lower sales of PNEUMOVAX 23 as the market continues to shift toward newer adult

-- 4 of 14 --

- 5 -
pneumococcal conjugate vaccines. Pharmaceutical sales growth for the full year of 2023 was
14% excluding LAGEVRIO and the unfavorable impact of foreign exchange.
Full-year 2023 Animal Health sales grew 1% to $5.6 billion. Excluding the unfavorable
impact of foreign exchange, Animal Health sales grew 3%, primarily due to higher pricing. Full-
year sales growth was also driven by higher demand for livestock products, led by poultry and
swine products, partially offset by lower demand for ruminant products. Sales of BRAVECTO
were $1.1 billion in 2023, which represented growth of 4%, or 5% excluding the impact of
foreign exchange, primarily reflecting higher pricing.
Fourth-Quarter and Full-Year Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Fourth Quarter 2023
Cost of sales 	$3,911 	$454 	$117 	$- 	$3,340
Selling, general and administrative 	2,804 	24 	29 	- 	2,751
Research and development 	9,628 	790 	- 	- 	8,838
Restructuring costs 	255 	- 	255 	- 	-
Other (income) expense, net 	78 	(35) 	- 	(61) 	174
Fourth Quarter 2022
Cost of sales 	$3,881 	$482 	$38 	$- 	$3,361
Selling, general and administrative 	2,687 	39 	20 	- 	2,628
Research and development 	3,775 	740 	- 	- 	3,035
Restructuring costs 	49 	- 	49 	- 	-
Other (income) expense, net 	(75) 	(69) 	- 	80 	(86)
3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a
result of acquisitions of businesses, intangible asset impairment charges and expense or income related to changes in the
estimated fair value measurement of liabilities for contingent consideration. R&D expenses include intangible asset impairment
charges of $779 million in both the fourth quarter and full year of 2023 related to gefapixant and $780 million and $1.7 billion in the
fourth quarter and full year of 2022, respectively, largely related to nemtabrutinib. Also includes integration, transaction and certain
other costs associated with acquisitions and divestitures, as well as amortization of intangible assets related to collaborations and
licensing arrangements.

-- 5 of 14 --

- 6 -
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs 3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Certain
Other
Items
Non-
GAAP2
Year Ended Dec. 31, 2023
Cost of sales 	$16,126 	$2,018 	$211 	$- 	$- 	$13,897
Selling, general and
administrative 	10,504 	86 	122 	- 	- 	10,296
Research and development 	30,531 	819 	1 	- 	- 	29,711
Restructuring costs 	599 	- 	599 	- 	- 	-
Other (income) expense, net 	466 	(47) 	- 	(279) 	573 	219
Year Ended Dec. 31, 2022
Cost of sales 	$17,411 	$2,059 	$205 	$- 	$- 	$15,147
Selling, general and
administrative 	10,042 	176 	94 	- 	- 	9,772
Research and development 	13,548 	1,676 	30 	- 	- 	11,842
Restructuring costs 	337 	- 	337 	- 	- 	-
Other (income) expense, net 	1,501 	(207) 	- 	1,348 	- 	360
GAAP Expense, EPS and Related Information
Gross margin was 73.3% for the fourth quarter of 2023 compared with 71.9% for the
fourth quarter of 2022. The increase was primarily due to the favorable impacts of lower
LAGEVRIO sales, which have a low gross margin, lower manufacturing facilities costs and
product mix, partially offset by the unfavorable impacts of foreign exchange and higher
restructuring costs. Gross margin was 73.2% for the full year of 2023 compared with 70.6% for
the full year of 2022. The increase was primarily due to the favorable impacts of lower
LAGEVRIO sales, product mix, lower manufacturing facilities costs, and lower revenue from
third-party manufacturing arrangements, partially offset by the unfavorable impact of foreign
exchange.
Selling, general and administrative (SG&A) expenses were $2.8 billion in the fourth
quarter of 2023, an increase of 4% compared with the fourth quarter of 2022. The increase was
primarily due to higher administrative costs, including higher compensation and benefit costs,
partially offset by lower promotional spending. Full-year 2023 SG&A expenses were $10.5
billion, an increase of 5% compared with the full year of 2022. The increase was primarily due to
higher administrative costs, including higher compensation and benefit costs, and higher
promotional spending, partially offset by the favorable impact of foreign exchange and lower
acquisition- and divestiture-related costs.
R&D expenses were $9.6 billion in the fourth quarter of 2023 compared with $3.8 billion
in the fourth quarter of 2022. R&D expenses were $30.5 billion for the full year of 2023
compared with $13.5 billion for the full year of 2022. The increase in the fourth quarter and full
year of 2023 reflects a $5.5 billion charge for the collaboration with Daiichi Sankyo, and higher
development costs due to spending on clinical programs, including newly acquired programs, as
well as higher compensation and benefit costs (reflecting in part increased headcount). The

-- 6 of 14 --

- 7 -
increase in R&D expenses for the full year was also due to charges of $11.4 billion in the
aggregate for the acquisitions of Prometheus Biosciences, Inc. (Prometheus) and Imago
BioSciences, Inc. (Imago). The increase in R&D expenses for the full year was partially offset by
lower intangible asset impairment charges in 2023 and charges of $690 million in the aggregate
in 2022 for collaboration and licensing agreements with Moderna, Inc. (Moderna), Orna
Therapeutics (Orna) and Orion Corporation (Orion).
Other (income) expense, net, was $78 million of expense in the fourth quarter of 2023
compared with $75 million of income in the fourth quarter of 2022, primarily due to higher
exchange losses and higher net interest expense, partially offset by net gains from investments
in equity securities for the fourth quarter of 2023 compared with net losses from investments in
equity securities for the fourth quarter of 2022, and lower pension settlement costs. Other
(income) expense, net, was $466 million of expense in the full year of 2023 compared with $1.5
billion of expense in the full year of 2022, primarily due to net gains from investments in equity
securities in 2023 compared with net losses from investments in equity securities in 2022, and
lower pension settlement costs, partially offset by a $572.5 million charge in 2023 related to
settlements with certain plaintiffs in the Zetia antitrust litigation.
The effective tax rate was 40.1% for the fourth quarter of 2023 compared with 14.1% in
the fourth quarter of 2022. The effective tax rate for the fourth quarter of 2023 includes a 29.2
percentage point impact resulting from the charge for the Daiichi Sankyo collaboration. The
effective tax rate was 80.0% for the full year of 2023 compared with 11.7% for the full year of
2022. The full-year 2023 effective tax rate reflects an aggregate 65.6 percentage point
unfavorable impact, resulting from charges for asset acquisitions (for which no tax benefits were
recognized) as well as the charge for the Daiichi Sankyo collaboration.
GAAP loss per share was $0.48 for the fourth quarter of 2023 compared with EPS of
$1.18 for the fourth quarter of 2022, primarily driven by the charge in 2023 related to the
collaboration with Daiichi Sankyo, the unfavorable impact of foreign exchange and higher
restructuring costs, partially offset by a beneficial impact from the tax rate and operational
strength in the business. GAAP EPS was $0.14 for the full year of 2023 compared with EPS of
$5.71 for the full year of 2022. The EPS decline in 2023 was primarily due to higher charges for
certain business development transactions, the unfavorable impact of foreign exchange and the
tax rate, as well as a charge related to settlements with certain plaintiffs in the Zetia antitrust
litigation, partially offset by the beneficial impacts of operational strength in the business, better
performance from equity investments and lower intangible asset impairment charges.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 77.2% for the fourth quarter of 2023 compared with 75.7%
for the fourth quarter of 2022. Non-GAAP gross margin was 76.9% for the full year of 2023
compared with 74.4% for the full year of 2022. The non-GAAP gross margin improvement in the
fourth quarter and full year of 2023 was primarily due to the favorable impacts of lower
LAGEVRIO sales, which have a low gross margin, product mix, and lower manufacturing
facilities costs. The increase in non-GAAP gross margin for the full year was also due to lower

-- 7 of 14 --

- 8 -
revenue from third-party manufacturing arrangements. The non-GAAP gross margin
improvement in the fourth quarter and full year of 2023 was partially offset by the unfavorable
impact of foreign exchange.
Non-GAAP SG&A expenses were $2.8 billion for the fourth quarter of 2023 compared
with $2.6 billion for the fourth quarter of 2022. The increase was primarily due to higher
administrative costs, including higher compensation and benefit costs, partially offset by lower
promotional spending. Full-year 2023 non-GAAP SG&A expenses were $10.3 billion, an
increase of 5% compared with the full year of 2022. The increase was primarily due to higher
administrative costs, including higher compensation and benefit costs, and higher promotional
spending, partially offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $8.8 billion in the fourth quarter of 2023 compared with
$3.0 billion in the fourth quarter of 2022. Non-GAAP R&D expenses were $29.7 billion for the
full year of 2023 compared with $11.8 billion for the full year of 2022. The increase in the fourth
quarter and full year of 2023 reflects a $5.5 billion charge for the collaboration with Daiichi
Sankyo, and higher development costs due to spending on clinical programs, including newly
acquired programs, as well as higher compensation and benefit costs (reflecting in part
increased headcount). The increase in non-GAAP R&D expenses for the full year was also due
to charges of $11.4 billion in the aggregate for the acquisitions of Prometheus and Imago. The
increase in R&D expenses for the full year was partially offset by charges of $690 million in the
aggregate in 2022 for collaboration and licensing agreements with Moderna, Orna and Orion.
Non-GAAP other (income) expense, net, was $174 million of expense in the fourth
quarter of 2023 compared with $86 million of income in the fourth quarter of 2022, primarily due
to higher exchange losses and higher net interest expense, partially offset by lower pension
settlement costs. Non-GAAP other (income) expense, net, was $219 million of expense in the
full year of 2023 compared with $360 million of expense in the full year of 2022, primarily due to
lower pension settlement costs.
The non-GAAP effective tax rate was 114.2% for the fourth quarter of 2023 compared
with 15.6% in the fourth quarter of 2022. The non-GAAP effective tax rate for the fourth quarter
of 2023 includes a 101.1 percentage point unfavorable impact resulting from the charge for the
Daiichi Sankyo collaboration. The non-GAAP effective tax rate was 35.8% for the full year of
2023 compared with 14.2% for the full year of 2022. The full-year 2023 non-GAAP effective tax
rate reflects an aggregate 21.2 percentage point unfavorable impact, resulting from charges for
asset acquisitions (for which no benefits were recognized) as well as the charge for the Daiichi
Sankyo collaboration.
Non-GAAP EPS was $0.03 for the fourth quarter of 2023 compared with $1.62 for the
fourth quarter of 2022. The non-GAAP EPS decline in the fourth quarter was primarily due to the
charge in 2023 related to the collaboration with Daiichi Sankyo and the unfavorable impact of
foreign exchange, partially offset by a beneficial impact from the tax rate and operational
strength in the business. Non-GAAP EPS was $1.51 for the full year of 2023 compared with

-- 8 of 14 --

- 9 -
$7.48 for the full year of 2022. The non-GAAP EPS decline for the full year was primarily due to
higher charges for certain business development transactions, the unfavorable impact of foreign
exchange and the tax rate, partially offset by operational strength in the business.
A reconciliation of GAAP to non-GAAP net (loss) income and (loss) earnings per share
is provided in the table that follows.
2024 Restructuring Program
Merck recently approved a new restructuring program (2024 Restructuring Program)
intended to continue the optimization of the company’s Human Health global manufacturing
network as the future pipeline shifts to new modalities, and also to optimize the Animal Health
global manufacturing network to improve supply reliability and increase efficiency. The company
recorded charges in its GAAP results of $190 million related to the 2024 Restructuring Program
for the fourth quarter and full year of 2023.
Pipeline and Portfolio Highlights
In the fourth quarter, Merck continued to make significant progress advancing its broad
portfolio and pipeline across key therapeutic areas, representing continued momentum toward
addressing patient needs.
In oncology, Merck received multiple U.S. Food and Drug Administration (FDA)
approvals, including KEYTRUDA plus Padcev for the first-line treatment of adult patients with
locally advanced or metastatic urothelial cancer and WELIREG for the treatment of certain
patients with previously treated advanced RCC, among other approvals. The FDA also
accepted and granted Priority Review to Merck and Daiichi Sankyo’s Biologics License
Application (BLA) for patritumab deruxtecan for the treatment of certain patients with previously
treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). The
Fourth Quarter 	Year Ended
$ in millions, except EPS amounts 	2023 	2022
Dec. 31,
2023
Dec. 31,
2022
EPS
GAAP EPS 	$(0.48) 	$1.18 	$0.14 	$5.71
Difference 	0.51 	0.44 	1.37 	1.77
Non-GAAP EPS that excludes items listed below2 	$0.03 	$1.62 	$1.51 	$7.48
Net (Loss) Income
GAAP net (loss) income 1 	$(1,226) 	$3,017 	$365 	$14,519
Difference 	1,292 	1,112 	3,472 	4,486
Non-GAAP net income that excludes items listed below1,2 	$66 	$4,129 	$3,837 	$19,005
Excluded Items:
Acquisition- and divestiture-related costs 3 	$1,233 	$1,192 	$2,876 	$3,704
Restructuring costs 	401 	107 	933 	666
(Income) loss from investments in equity securities 	(61) 	80 	(279) 	1,348
Charge for Zetia antitrust litigation settlements 	- 	- 	573 	-
Increase to net loss/decrease to net income before taxes 	1,573 	1,379 	4,103 	5,718
Estimated income tax (benefit) expense 	(281) 	(267) 	(631) 	(1,232)
Increase to net loss/decrease to net income 	$1,292 	$1,112 	$3,472 	$4,486

-- 9 of 14 --

- 10 -
FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 26, 2024. In
addition, Merck showed meaningful progress in its robust oncology pipeline, initiating Phase 3
trials for four investigational medicines, including bomedemstat (LSD1 inhibitor), nemtabrutinib
(BTK inhibitor), MK-2870 (anti-TROP2 antibody-drug conjugate) and MK-5684 (CYP11A1
inhibitor).
In vaccines, Merck received Priority Review from the FDA for a BLA for V116, the
company’s investigational, 21-valent pneumococcal conjugate vaccine specifically designed to
protect adults, based on results from multiple Phase 3 trials. The FDA set a PDUFA date of
June 17, 2024. If approved, V116 would be the first pneumococcal conjugate vaccine to include
serotypes responsible for approximately 83 percent of adult invasive pneumococcal disease in
individuals 65 and older, according to U.S. Centers for Disease Control and Prevention data
from 2018-2021.
In hospital acute care, the European Commission (EC) approved PREVYMIS for
prevention of cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients and
extended 200-day dosing in adult hematopoietic stem cell transplant (HSCT) recipients who are
at high risk for late CMV infection and disease.
Merck continued to augment its pipeline through business development, and in January
2024, entered into a definitive agreement to acquire Harpoon Therapeutics, Inc. (Harpoon), for
an approximate total equity value of $680 million, further diversifying its oncology pipeline.
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Approved Expanded Indication for KEYTRUDA Plus Padcev as First-
Line Treatment for Adult Patients With Locally Advanced or Metastatic
Urothelial Cancer, Based on Results From Phase 3 KEYNOTE-A39 Trial
(Read
Announcement)
FDA Approved Merck’s WELIREG as Treatment for Patients With Advanced
RCC Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI, Based on
Results From LITESPARK-005 Trial
(Read
Announcement)
FDA Approved Merck’s KEYTRUDA Plus Chemoradiotherapy as Treatment
for Patients With FIGO 2014 Stage III-IVA Cervical Cancer, Based on
Results From Phase 3 KEYNOTE-A18 Trial
(Read
Announcement)
FDA Approved Merck’s KEYTRUDA Plus Chemotherapy as First-Line
Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, Based on
Results From Phase 3 KEYNOTE-859 Trial
(Read
Announcement)
FDA Approved Merck’s KEYTRUDA Plus Gemcitabine and Cisplatin as
Treatment for Patients With Locally Advanced Unresectable or Metastatic
Biliary Tract Cancer, Based on Results From Phase 3 KEYNOTE-966 Trial
(Read
Announcement)
EC Approved KEYTRUDA Plus Chemotherapy for New First-Line
Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in
Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer,
Based on Results From Phase 3 KEYNOTE-859 and KEYNOTE-966 Trials
(Read
Announcement)
FDA Granted Priority Review to Merck and Daiichi Sankyo’s BLA for
Patritumab Deruxtecan for the Treatment of Certain Patients With
Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC,
Based on Results From Phase 2 HERTHENA-Lung01 Trial; FDA Set
PDUFA Date of June 26, 2024
(Read
announcement)

-- 10 of 14 --

- 11 -
Merck Announced Phase 3 Trial Initiations for Bomedemstat, Nemtabrutinib,
MK-2870 and MK-5684, Four Investigational Candidates From Promising
Hematology and Oncology Pipeline
(Read
announcement)
Merck and Moderna Initiated INTerpath-002, a Phase 3 Study Evaluating
V940 (mRNA-4157) in Combination With KEYTRUDA for Adjuvant
Treatment of Patients With Certain Types of Resected NSCLC
(Read
Announcement)
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as
Adjuvant Therapy for Patients With RCC at an Increased Risk of
Recurrence Following Nephrectomy, Based on Results From Phase 3
KEYNOTE-564 Trial
(Read
Announcement)
KEYTRUDA Significantly Improved Disease-Free Survival as Adjuvant
Therapy Versus Observation in High-Risk Patients With Localized Muscle-
Invasive and Locally Advanced Urothelial Carcinoma After Surgery, Based
on Results From Phase 3 AMBASSADOR/KEYNOTE-123 Trial
(Read
Announcement)
Moderna and Merck Announced V940 (mRNA-4157) in Combination With
KEYTRUDA Demonstrated Continued Improvement in Recurrence-Free
Survival and Distant Metastasis-Free Survival in Patients With High-Risk
Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
at Three Years, Based on Results From Phase 2b Randomized KEYNOTE-
942/mRNA-4157-P201 Study
(Read
Announcement)
Vaccines
FDA Granted Priority Review to Merck’s New BLA for V116, an
Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically
Designed to Protect Adults, Based on Results From Multiple Phase 3 Trials;
FDA Set PDUFA Date of June 17, 2024
(Read
Announcement)
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate
Vaccine Specifically Designed to Protect Adults, Demonstrated Superior
Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in
Adults 50 Years of Age and Older, Based on Results From Phase 3
STRIDE-3 Trial
(Read
Announcement)
Full-Year 2024 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2024
Sales * 	$62.7 to $64.2 billion
Non-GAAP gross margin 2 	Approximately 80.5%
Non-GAAP operating expenses 2** 	$25.1 to $26.1 billion
Non-GAAP other (income) expense, net2 	Approximately $200 million expense
Non-GAAP effective tax rate 2 	14.5% to 15.5%
Non-GAAP EPS2*** 	$8.44 to $8.59
Share count (assuming dilution) 	Approximately 2.54 billion
*The company does not have any non-GAAP adjustments to sales.
**Includes approximately $650 million of R&D expense related to the recently announced Harpoon acquisition, which is expected to close
in the first half of 2024. Outlook does not assume any additional significant potential business development transactions.
***Includes a one-time charge of approximately $0.26 per share related to the Harpoon acquisition.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the company’s future GAAP results.

-- 11 of 14 --

- 12 -
Merck anticipates full-year 2024 sales to be between $62.7 billion and $64.2 billion,
including a negative impact of foreign exchange of approximately 2% at mid-January 2024
exchange rates. The negative impact is primarily due to the devaluation of the Argentine peso,
which the company expects will largely be offset by inflation-related price increases, consistent
with market practice.
The outlook for operating expenses reflects incremental R&D spending expected to be
incurred to advance the development of promising programs related to the acquisitions of
Prometheus, Imago and Harpoon, as well as the collaborations with Daiichi Sankyo and Kelun-
Biotech.
Merck’s full-year non-GAAP effective income tax rate is expected to be between 14.5%
and 15.5%.
Merck expects full-year 2024 non-GAAP EPS to be between $8.44 and $8.59, including
a negative impact of foreign exchange of approximately $0.25 per share. In 2023, non-GAAP
EPS of $1.51 was negatively impacted by charges of $6.21 per share related to certain
acquisitions and collaboration agreements.
In early January 2024, Merck announced the acquisition of Harpoon, which is expected
to close in the first half of 2024, and result in a non-tax deductible charge of approximately $650
million of R&D expense included in non-GAAP results. The impact of the transaction on
expected full-year non-GAAP EPS is approximately $0.26 per share, which is included in the
2024 outlook.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Thursday, Feb. 1, at 9 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
prepared remarks and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (800) 779-6561 (U.S. and Canada Toll-Free)
or (773) 756-4619 and using the access code 5958465.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of

-- 12 of 14 --

- 13 -
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on X (formerly
Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the
impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of international economies
and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022,
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).

-- 13 of 14 --

- 14 -
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 14 of 14 --